What Researchers Did
Researchers conducted a systematic review of four randomized controlled trials to evaluate the efficacy and safety of various therapies for delayed encephalopathy after acute carbon monoxide poisoning (DEACMP).
What They Found
The review identified four randomized controlled trials, finding that both hyperbaric oxygen (HBO) and mesenchymal stem cell (MSC) transplantation were effective for DEACMP, with MSC appearing superior to HBO. Adding dexamethasone, N-butylphthalide, or XingZhi-YiNao granules to HBO, or butylphthalide to MSC, improved neurological recovery without significantly increasing adverse events.
What This Means for Canadian Patients
Canadian patients experiencing delayed encephalopathy after carbon monoxide poisoning may benefit from therapies like hyperbaric oxygen or mesenchymal stem cell transplantation. Combining these treatments with agents such as dexamethasone or N-butylphthalide could further enhance neurological recovery.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian participants or specific Canadian healthcare contexts.
Study Limitations
A limitation of this review is the small number of included randomized controlled trials (only four), suggesting the need for further robust studies to confirm these findings.